Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)’s share price traded up 5.3% on Thursday . The company traded as high as $151.79 and last traded at $149.49, with a volume of 3,289,147 shares. The stock had previously closed at $141.91.

A number of equities research analysts have recently commented on the stock. SunTrust Banks Inc. upgraded shares of Jazz Pharmaceuticals PLC from a “neutral” rating to a “buy” rating and increased their target price for the company from $164.00 to $200.00 in a research report on Monday, April 25th. Leerink Swann reiterated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Saturday, April 23rd. Deutsche Bank AG reiterated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, June 2nd. Mizuho reiterated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research report on Monday, June 6th. Finally, Zacks Investment Research upgraded shares of Jazz Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, April 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $185.36.

The company has a market capitalization of $9.23 billion and a P/E ratio of 28.83. The firm has a 50-day moving average of $142.53 and a 200 day moving average of $136.99.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported $2.26 EPS for the quarter, missing the consensus estimate of $2.31 by $0.05. During the same quarter in the prior year, the firm earned $1.99 EPS. The business had revenue of $336 million for the quarter, compared to the consensus estimate of $338.86 million. The business’s quarterly revenue was up 8.6% on a year-over-year basis. On average, equities research analysts forecast that Jazz Pharmaceuticals PLC will post $11.14 EPS for the current year.

In other news, CMO Karen L. Smith purchased 580 shares of the business’s stock in a transaction dated Wednesday, July 13th. The stock was acquired at an average price of $143.63 per share, with a total value of $83,305.40. Following the purchase, the chief marketing officer now directly owns 13,574 shares of the company’s stock, valued at approximately $1,949,633.62. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Heather Ann Mcsharry sold 697 shares of Jazz Pharmaceuticals PLC stock in a transaction on Monday, May 16th. The stock was sold at an average price of $145.20, for a total value of $101,204.40. Following the transaction, the director now directly owns 5,396 shares of the company’s stock, valued at approximately $783,499.20. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently added to or reduced their stakes in the company. Mitsubishi UFJ Kokusai Asset Management CO. LTD. increased its position in Jazz Pharmaceuticals PLC by 8.3% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management CO. LTD. now owns 7,690 shares of the specialty pharmaceutical company’s stock valued at $1,081,000 after buying an additional 590 shares during the period. Condor Capital Management increased its position in Jazz Pharmaceuticals PLC by 2.3% in the fourth quarter. Condor Capital Management now owns 7,727 shares of the specialty pharmaceutical company’s stock valued at $1,086,000 after buying an additional 173 shares during the period. TD Asset Management Inc. increased its position in Jazz Pharmaceuticals PLC by 3.9% in the fourth quarter. TD Asset Management Inc. now owns 16,076 shares of the specialty pharmaceutical company’s stock valued at $2,260,000 after buying an additional 600 shares during the period. Trexquant Investment LP increased its position in Jazz Pharmaceuticals PLC by 193.7% in the fourth quarter. Trexquant Investment LP now owns 18,500 shares of the specialty pharmaceutical company’s stock valued at $2,600,000 after buying an additional 12,200 shares during the period. Finally, I.G. Investment Management LTD. increased its position in Jazz Pharmaceuticals PLC by 0.5% in the fourth quarter. I.G. Investment Management LTD. now owns 20,182 shares of the specialty pharmaceutical company’s stock valued at $2,837,000 after buying an additional 108 shares during the period.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.